Coordinated expression of galectin-3 and galectin-3-binding sites in malignant mammary tumors: implications for tumor

J. Oliveira, A.J. Matos, J. Gomes, M. Vilanova, V. Hespanhol, A. Manninen, G.R. Rutteman, R. Chammas, F. Gartner, E.S. Bernardes

    Research output: Contribution to journalArticleAcademicpeer-review


    Glycobiology. 2010 Nov;20(11):1341-52. Epub 2010 Jun 29. Coordinated expression of galectin-3 and galectin-3-binding sites in malignant mammary tumors: implications for tumor metastasis. de Oliveira JT, de Matos AJ, Gomes J, Vilanova M, Hespanhol V, Manninen A, Rutteman G, Chammas R, Gärtner F, Bernardes ES. Institute of Molecular Pathology and Immunology (IPATIMUP), University of Porto, Porto, Portugal. Abstract Galectin-3 is a glycan-binding protein that mediates cell-cell and/or cell-extracellular matrix (ECM) interactions. Although galectin-3 is implicated in the progression of various types of cancers, the mechanisms by which galectin-3 enhances metastasis remain unclear. In order to elucidate the role of galectin-3 in the complex multistage process of cancer metastasis, we examined galectin-3 and galectin-3-binding site expression in a series of 82 spontaneous canine mammary tumors (CMT) and two CMT cell lines. Benign CMT tumors exhibited strong nuclear/cytoplasmic galectin-3 immunostaining, whereas malignant CMT tumors and metastases exhibited dramatically decreased galectin-3 expression with the majority of the immunostaining confined to the cytoplasm. Interestingly, intravascular tumor cells overexpressed galectin-3 regardless of their location. CMT-U27 xenografts displayed the same pattern of galectin-3 expression found in spontaneous malignant CMT. In parallel with the downregulation of galectin-3, malignant CMT displayed an overall loss of galectin-3-binding sites in the ECM and focal expression of galectin-3-binding sites mainly detected in intravascular tumor cells and endothelium. Furthermore, loss of galectin-3-binding sites was correlated with the downregulation of GLT25D1, a β (1-O) galactosyltransferase that modifies collagen, and upregulation of stromal galectin-1. Finally, GLT25D1 mRNA expression was strikingly downregulated in malignant CMT-U27 compared with the benign cell line, and its expression was further decreased in a galectin-3 knockdown CMT-U27 cell line. We therefore hypothesized that the loss of galectin-3-binding sites in the ECM in conjunction with the overexpression of galectin-3 in specific tumor cell subpopulations are crucial events for the development of mammary tumor metastases. PMID: 20591828 [PubMed - in process]
    Original languageUndefined/Unknown
    Pages (from-to)1341-1352
    Number of pages13
    Issue number11
    Publication statusPublished - 2010

    Cite this